Skip to Main Content

A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Conditions

Larynx | Soft Tissue | Unknown Sites

Phase II

What is the purpose of this trial?

This randomized phase II trial studies how well ficlatuzumab with or without cetuximab work in treating patients with head and neck squamous cell carcinoma that has come back or spread to other places in the body and resistant to cetuximab treatment. Monoclonal antibodies, such as ficlatuzumab and cetuximab, may block growth signals that lets a tumor cell survive and reproduce, and helps the immune system recognize and fight head and neck squamous cell carcinoma.

  • Trial with
    University of Arizona Cancer Center
  • Start Date
    10/15/2019
  • End Date
    12/30/2020

For more information about this study, contact:

Monica Tawadros

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/07/2020
  • Study HIC
    #2000022999